skip to Main Content

Expert Highlights Importance of Biomarker Testing in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Biomarker testing and precision medicine have steadily become a growing topic in different cancer settings, including pancreatic cancer. Mutations in patients with this disease are not uncommon, such as DNA damage repair (DDR) mutations, and can help direct which therapies patients should be given to lengthen their survival.

“We are making progress in the outcomes for patients with pancreatic cancer,” Michael J. Pishvaian, MD, PhD, said during the virtual 2020 International Society of Gastrointestinal Oncology (ISGIO) Conference.1 “Twenty years ago, the median overall survival [OS] was only 6 months, but in the control arms of some recently presented studies with FOLFIRINOX [folinic acid, fluorouracil, irinotecan, and oxaliplatin], the median OS was almost 15 months. So, we are going in the right direction.”    Read more… 

Back To Top